Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FRFEQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TAA-013
|
|||||
| Synonyms |
TAA 013; TAA013; Anti-HER2 ADC (TOT Biopharm); Trastuzumab antibody drug conjugate (TOT Biopharm)
Click to Show/Hide
|
|||||
| Organization |
Tot Biopharm Co. Ltd.
|
|||||
| Drug Status |
Terminated in phase 3
|
|||||
| Indication |
In total 2 Indication(s)
HER2(+) breast cancer [ICD11:2C60-2C65]
Terminated in phase 3
HER2(-) breast cancer [ICD11:2C60-2C65]
Terminated in phase 3
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.